In addition, another study described that SHMT2 and BCL2 cooperated to promote the occurrence of lymphoma through the silencing of epigenetic inhibitors, as the enhancement of SHMT2 metabolic enzyme activity was sufficient to convert normal B cells into B-cell lymphoma (37). The gene discussed is SHMT2; the disease is B-cell non-Hodgkin lymphoma.